Impact of surveillance on survival after laryngeal cancer in the medicare population

Laryngoscope

Volumn 119, Issue 12, 2009, Pages 2337-2344

  Francis, David O ^a   Yueh, Bevan ^b   Weymuller Jr , Ernest A ^a   Merati, Albert L ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Laryngeal cancer; Recurrence; Surveillance; Survival

Indexed keywords

AGED; ARTICLE; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; DATA BASE; FEMALE; HEAD AND NECK CANCER; HUMAN; LARYNX CANCER; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MEDICARE; NATIONAL HEALTH ORGANIZATION; POPULATION RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECURRENT CANCER; RISK ASSESSMENT; CANCER REGISTRY; COMPARATIVE STUDY; CONFIDENCE INTERVAL; FOLLOW UP; LARYNX TUMOR; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; RISK; STATISTICS; SURVIVAL RATE; TUMOR RECURRENCE; UNITED STATES;

AGED; COMBINED MODALITY THERAPY; CONFIDENCE INTERVALS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LARYNGEAL NEOPLASMS; MALE; MEDICARE; NEOPLASM RECURRENCE, LOCAL; ODDS RATIO; PROGNOSIS; RETROSPECTIVE STUDIES; SEER PROGRAM; SURVIVAL RATE; UNITED STATES;

EID: 73949131164     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1002/lary.20576     Document Type: Article

References (34)

1. Wong LY, Wei WI, Lam LK, Yuen AP. Salvage of recurrent head and neck squamous cell carcinoma after primary curative surgery. Head Neck 2003;25:953-959.
2. Ritoe SC, Bergman H, Krabbe PF, et al. Cancer recurrence after total laryngectomy: treatment options, survival, and complications. Head Neck 2006;28:383-388.
3. Ritoe SC, de Vegt F, Scheike IM, et al. Effect of routine follow-up after treatment for laryngeal cancer on life expectancy and mortality: results of a Markov model analysis. Cancer 2007;109:239-247.
4. Leon X, Lopez M, Garcia J, Viza I, Gich I, Quer M. Recurrent laryngeal squamous cell carcinoma: rTNM versus composite laryngeal recurrence staging system. Proposal for a modification of the CLRSS to improve patient classification. Head Neck 2008;30:939-945.
5. Carvalho AL, Nishimoto IN, Califano JA, Kowalski LP. Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database. Int J Cancer 2005;114:806-816.
6. Hoffman HT, Porter K, Karnell LH, et al. Laryngeal cancer in the United States: changes in demographics, patterns of care, and survival. Laryngoscope 2006;116:1-13.
7. Cosetti M, Yu GP, Schantz SP. Five-year survival rates and time trends of laryngeal cancer in the US population. Arch Otolaryngol Head Neck Surg 2008;134:370-379.
8. Paniello RC, Virgo KS, Johnson MH, Clemente MF, Johnson FE. Practice patterns and clinical guidelines for posttreatment follow-up of head and neck cancers: a comparison of 2 professional societies. Arch Otolaryngol Head Neck Surg 1999;125:309-313.
9. Albright JT, Karpati R, Topham AK, Spiegel JR, Sataloff RT. Second malignant neoplasms in patients under 40 years of age with laryngeal cancer. Laryngoscope 2001;111:563-567.
10. Agrawal A, deSilva BW, Buckley BM, Schuller DE. Role of the physician versus the patient in the detection of recurrent disease following treatment for head and neck cancer. Laryngoscope 2004;114:232-235.
11. Ritoe SC, Krabbe PF, Kaanders JH, van den Hoogen FJ, Verbeek AL, Marres HA. Value of routine follow-up for patients cured oflaryngeal carcinoma. Cancer 2004;101:1382-1389.
12. Schwartz DL, Barker J Jr, Chansky K, et al. Postradiotherapy surveillance practice for head and neck squamous cell carcinoma-too much for too little? Head Neck 2003;25:990-999.
13. Deleyiannis FW, Weymuller EA Jr, Garcia I, Potosky AL. Geographic variation in the utilization of esophagoscopy and bronchoscopy in head and neck cancer. Arch Otolaryngol Head Neck Surg 1997;123:1203-1210.
14. Groome PA, O'Sullivan B, Irish JC, et al. Glottic cancer in Ontario, Canada and the SEER areas of the United States. Do different management philosophies produce different outcome profiles? J Clin Epidemiol 2001;54:301-315.
15. Virgo KS, Paniello RC, Johnson FE. Costs of posttreatment surveillance for patients with upper aerodigestive tract cancer. Arch Otolaryngol Head Neck Surg 1998;124:564-572.
16. The Complete Library of NCCN Oncology Practice Guidelines, Version 1. In: Network NCCN. Fort Washington, PA: National Comprehensive Cancer Network; 2001.
17. Marshak G, Brenner B, Shvero J, et al. Prognostic factors for local control of early glottic cancer: the Rabin Medical Center retrospective study on 207 patients. Int J Radiat Oncol Biol Phys 1999;43:1009-1013.
18. Ries LAG, Horner MJ, Young JL. Introduction. In: Ries LAG, Young JL, Keel GE, Eisner MP, Lin YD, Horner MJ, eds. SEER Survival Monograph: Cancer Survival Among Adults: U. S. SEER Program, 1988-2001, Patient and Tumor Characteristics. Bethesda, MD: National Cancer Institute, SEER Program, NIH Pub. No. 07-6215;2007:1-6.
19. Barzilai DA, Cooper KD, Neuhauser D, Rimm AA, Cooper GS. Geographic and patient variation in receipt of surveillance procedures after local excision of cutaneous melanoma. J Invest Dermatol 2004;122:246-255.
20. Baldwin LM, Adamache W, Klabunde CN, Kenward K, Dahlman C, L Warren J. Linking physician characteristics and medicare claims data: issues in data availability, quality, and measurement. Med Care 2002;40 (8 suppl): IV-82-95.
21. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-619.
22. The SEER Program Code Manual. Fritz A, Reis L, eds. Bethesda, MD: National Cancer Institute, 1998:1-180.
23. Johnson FE, Virgo KS, Clemente MF, Johnson MH, Paniello RC. How tumor stage affects surgeons' surveillance strategies after surgery for carcinoma of the upper aerodigestive tract. Cancer 1998;82:1932-1937.
24. Lacy PD, Kennedy JT, Piccirillo JF. Validation of the composite laryngeal recurrence staging system. Cancer 2004;101:761-767.
25. Ritoe SC, Verbeek AL, Krabbe PF, Kaanders JH, van den Hoogen FJ, Marres HA. Screening for local and regional cancer recurrence in patients curatively treated for laryngeal cancer: definition of a high-risk group and estimation of the lead time. Head Neck 2007;29:431-438.
26. de Visscher AV, Manni JJ. Routine long-term follow-up in patients treated with curative intent for squamous cell carcinoma of the larynx, pharynx, and oral cavity. Does it make sense? Arch Otolaryngol Head Neck Surg 1994;120:934-939.
27. Terhaard CH, Hordijk GJ, van den Broek P, et al. T3 laryngeal cancer: a retrospective study of the Dutch Head and Neck Oncology Cooperative Group: study design and general results. Clin Otolaryngol Allied Sci 1992;17:393-402.
28. Lacy PD, Piccirillo JF. Development of a new staging system for patients with recurrent laryngeal squamous cell carcinoma. Cancer 1998;83:910-917.
29. Paleri V, Wight RG, Davies GR. Impact of comorbidity on the outcome of laryngeal squamous cancer. Head Neck 2003;25:1019-1026.
30. Gourin CG, Podolsky RH. Racial disparities in patients with head and neck squamous cell carcinoma. Laryngoscope 2006;116:1093-1106.
31. Chen AY, Halpern M. Factors predictive of survival in advanced laryngeal cancer. Arch Otolaryngol Head Neck Surg 2007;133:1270-1276.
32. Reid BC, Warren JL, Rozier G. Comorbidity and early diagnosis of head and neck cancer in a Medicare population. Am J Prev Med 2004;27:373-378.
33. Rosselli Del Turco M, Palli D, Cariddi A, Ciatto S, Pacini P, Distante V. Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow-up. JAMA 1994;271:1593-1597.
34. Joseph E, Hyacinthe M, Lyman GH, et al. Evaluation of an intensive strategy for follow-up and surveillance of primary breast cancer. Ann Surg Oncol 1998;5:522-528.